BRAF Polyclonal Antibody

SKU: E-AB-70237

Size::120μL

Storage:Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping:The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.

Exp date:12 months

Category ID_II:Primary Antibodies

Category ID_III:Polyclonal Antibodies

Abbreviation:BRAF

Target Synonym:FLJ95109;94 kDa B raf protein;B raf 1;B Raf proto oncogene serine threonine protein kinase;B Raf proto oncogene;serine/threonine kinase;B RAF1;B-Raf proto-oncogene serine/threonine-protein kinase (p94);BRAF 1;BRAF;BRAF;BRAF1;cRmil;MGC126806;MGC138284;Murine sarcoma viral (v-raf) oncogene homolog B1;Murine sarcoma viral v raf oncogene homolog B1;NS7;Oncogen BRAF;oncogene BRAF1;p94;Proto-oncogene B-Raf;Proto-oncogene c-Rmil;RAFB 1;RAFB1;RMIL;Serine/threonine-protein kinase B-raf;v raf murine sarcoma viral oncogene homolog B;v raf murine sarcoma viral oncogene homolog B1;v-Raf murine sarcoma viral oncogene homolog B1

Research Areas:Cancer;Cell Biology;Signal Transduction

Conjugation:Unconjugated

Host:Rabbit

Species reactivity:Mouse;Rat

Application:IHC

Isotype:IgG

Clonality:Polyclonal

Clone NO.:

UNIProt ID:P28028

Accession:

Background:This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.

Concentration:0.74 mg/mL

Immunogen:KLH conjugated Synthetic peptide corresponding to Mouse B-Ra

Buffer:PBS with 0.02% sodium azide, 1% protective protein and 50% glycerol, pH7.4

Purification method:Affinity purification

Dilution:IHC 1:200-1:800

Calculated MW:

ObservedMW: